Claims

1. A method for treating Polypoidal Choroidal Vasculopathy (PCV) in a patient, wherein it is first established if the PCV is of AMD-type or non-AMD type and then the patient is treated according to usual AMD treatment schemes in case of AMD type PCV.
2. A method according to claim 1, wherein in case of non-AMD type PCV the patient is treated with a combination therapy including single or repeated applications of photodynamic therapy with Visudyne® (V®-PDT).
3. A method according to claim 2, wherein the combination therapy includes anti VEGF treatment.
4. A method according to claim 3, wherein the anti-VEGF treatment includes administration of a compound selected from aflibercept, ranibizumab, bevacizumap, or pegaptanip.
5. A method according to claim 1, wherein in case of AMD-type PCV the treatment is a monotherapy.
6. A method according to claim 1 or 5, wherein the treatment is an anti-VEGF therapy.
7. A method according to claim 1, 5 or 6, wherein the anti-VEGF compounds are selected from aflibercept, ranibizumab, bevacizumap, or pegaptanip.
8. A pharmaceutical composition comprising Visudyne® for PDT-treatment of non-AMD type PCV.
9. A pharmaceutical composition according claim 8 comprising Visudyne® for PDT-treatment of non-AMD type PCV in a combination therapy.
10. A pharmaceutical composition according claim 8 comprising Visudyne® for PDT-treatment of non-AMD type PCV in an anti-VEGF combination therapy.
11. A pharmaceutical composition according claim 10 comprising Visudyne® for PDT-treatment of non-AMD type PCV in a combination therapy comprising aflibercept, ranibizumab, bevacizumap, or pegaptanip.
12. A pharmaceutical composition comprising aflibercept, ranibizumab, bevacizumap, or pegaptanip for therapy of non-AMD type PCV.
13. A pharmaceutical composition comprising aflibercept for therapy of non-AMD type PCV.

14. A pharmaceutical composition for the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of AMD-type an AMD treatment is selected.
15. A pharmaceutical composition for the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is treated with a combination therapy including single or repeated applications of PDT with Visudyne®.
16. A pharmaceutical composition according to claim 15, wherein in case of AMD-type PCV a monotherapy is applied and in case of non-AMD type PCV a combination therapy is applied.
17. A pharmaceutical composition according to claim 16, wherein in case of non-AMD type PCV the anti-VEGF therapy is combined with comprising Visudyne® treatment.
18. A pharmaceutical composition according to claims 15, 16, and 17, wherein the anti-VEGF agent is selected from the group consisting of aflibercept, ranibizumab, bevacizumap, or pegaptanip.
19. A method for the treatment of PCV in a patient, wherein the method comprises
    a. an initial anti-VEGF-therapy
    b. a subsequent evaluation of the treatment response
    c. a subsequent single or repeated combination treatment comprising anti-VEGF-therapy in the case the patient does not responds to the initial VEGF therapy
20. A method according to claim 19 wherein the combination treatment comprises of PDT with Visudyne® wherein
    a. the pharmaceutical composition for anti-VEGF-therapy is administered to the patient and
    b. subsequently a PDT treatment with Visudyne® is performed at the same day as the anti-VEGF-therapy or 1-7 or 2-3 days after anti-VEGF-therapy.
21. A method according to claim 19, wherein the initial anti-VEGF-therapy comprises of a single injection or two, three, four, five, six or more injections of the pharmaceutical composition for anti-VEGF therapy each 4, 8, 12 or more weeks apart.

22. A method according to claim 19, wherein at least 3 doses of the anti-VEGF-therapy are administered every 4 weeks.
23. A method according to claim 19, wherein the evaluation of the treatment response is performed 4, 8, 12 or more weeks after the preceding anti-VEGF-therapy.
24. A method according to claim 19 wherein the secondary combination therapy is performed one, two, three, four, five, six or more times each 4, 8, 12 or more weeks apart.
25. A method according to claim, 19, 20, 21, 22, 23, or 24 wherein the anti-VEGF-therapy includes administration of a compound selected from aflibercept, ranibizumab, bevacizumap, or pegaptanip.
26. A method according to claim 1, wherein in case of non-AMD type PCV the patient is treated with a combination therapy including thermal laser therapy, which includes sub-threshold treatments.
27. A pharmaceutical composition for the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non AMD-type PCV the patient is treated with a combination therapy including thermal laser therapy, which includes sub-threshold treatments.

Claims

1. A pharmaceutical composition for use in the treatment of Polypoidal Choroidal Vasculopathy (PCV) comprising an anti-VEGF agent, wherein the treatment comprises
    a. an initial anti-VEGF-therapy
    b. a subsequent evaluation of the treatment response
    c. a subsequent single or repeated combination treatment comprising anti-VEGF-therapy in case the patient does not responds to the initial VEGF therapy.
2. A pharmaceutical composition for use in the treatment of PCV according to claim 1 wherein the combination treatment comprises PDT with Visudyne® and wherein
    a. the pharmaceutical composition for anti-VEGF-therapy is administered to the patient and
    b. subsequently a PDT treatment with Visudyne® is performed at the same day as the anti-VEGF-therapy or 1-7 or 2-3 days after anti-VEGF-therapy.
3. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein the initial anti-VEGF-therapy comprises a single injection or two, three, four, five, six or more injections of the pharmaceutical composition for anti-VEGF therapy each 4, 8, 12 or more weeks apart.
4. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein at least 3 doses of the anti-VEGF-therapy are administered every 4 weeks.
5. A pharmaceutical composition for use in the treatment of PCV according to claim 1, wherein the evaluation of the treatment response is performed 4, 8, 12 or more weeks after the preceding anti-VEGF-therapy.
6. A pharmaceutical composition for use in the treatment of PCV according to claim 1 wherein the secondary combination therapy is performed one, two, three, four, five, six or more times each 4, 8, 12 or more weeks apart.

7. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD-type or non-AMD type and then in case of AMD-type an AMD treatment is selected.
8. A pharmaceutical composition for use in the treatment of PCV according to claim 7, wherein the selected AMD treatment is a monotherapy.
9. A pharmaceutical composition for use in the treatment of PCV according to claim 8, wherein the monotherapy comprises an anti-VEGF agent.
10. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is treated with a combination therapy including thermal laser therapy, which includes sub-threshold treatments.
11. A pharmaceutical composition for use in the treatment of PCV comprising an anti-VEGF agent wherein it is first established if the PCV is of AMD type or non-AMD type and then in case of non-AMD type PCV the patient is treated with a combination therapy including single or repeated applications of photodynamic therapy with Visudyne® (V®-PDT).
12. A pharmaceutical composition for use in the treatment of PCV according to claim 1 - 11, wherein the anti-VEGF agent is selected from the group consisting of aflibercept, ranibizumab, bevacizumap, or pegaptanip.
13. A pharmaceutical composition for use in the treatment of PCV according to claim 1 - 12, wherein the anti-VEGF agent is aflibercept.